GCK-MODY diabetes course in persons over 18 years of age: prospective observation

Most young patients with hyperglycemia have type 1 diabetes and type 2 diabetes but up to 10% of all cases of the disease occur in MODY (Maturity Onset Diabetes of the Young). Published abstracts show features of the debut, laboratory and genetic characteristics of MODY in the Russian population. However there is a small amount of data on the clinical course of this nosology in the Russian Federation.

Aim: To investigate the characteristics of the 3-year course of GCK-MODY diagnosed after 18 years.

Materials and methods: 85 probands and 46 relatives of the first and second degrees of kinship with a clinical diagnosis of GCK-MODY were examined: biochemical and hormonal blood tests, ultrasound, molecular genetic studies. Patients were invited for a follow-up visit 3 years after verification of the pathogenic mutations associated with GCK-MODY. Examination, biochemical and hormonalanalyzes , ultrasound were done in second visit.

Results: The diagnosis GCK-MODY was verified by a molecular genetic study in 25 probands (29.4%). In 33 of 46 (71.7%) relatives of patients with GCK-MODY were diagnosed identical mutations. In 31 patients with GCK-MODY diagnosed after 18 years, a dynamic observation was performed for three years. Most patients over 18 years of age did not have clinical manifestations of carbohydrate metabolism disorders when diagnosing GCK-MODY and follow up visit. Skin rashes and allergic reactions prevailed among concomitant pathologies. Patients with GCK-MODY had preserved β-cell secretion, HbA1c targets were achieved. Low fasting hyperglycemia prevailed which persisted even after treatment correction. Among the characteristics of carbohydrate metabolism, biochemical, lipid and hormonal parameters during GCK-MODY verification and after three years of observation no significant differences were obtained, which indicates a stable course of the disease. Half of the patients achieved normoglycemia by rational nutrition, two people with GCK-MODY within three years after determining the diagnosis were transferred from insulin therapy to oral glucose-lowering drugs. Among oral glucose-lowering drugs prior to GCK-MODY verification most patients used metformin, 3 years later — dipeptidyl peptidase-4 inhibitors.

Conclusion. The results of a three-year follow-up of a group of patients with GCK-MODY demonstrate a non-progressive course of this type of diabetes with stable indicators of carbohydrate metabolism and low fasting hyperglycemia that persists after 3 years of observation. With the verification of GCK-MODY and the achievement of the target values of glycated hemoglobin and postprandial glycaemia by rational nutrition, even if a low level of fasting hyperglycemia is determined, the prescription of oral glucose-lowering drugs is not indicated in most cases.

1. Rymar OD, Ovsjannikova AK, Mustafina SV, et al. Role of mody-diabetes in structure of morbidity rate of diabetes mellitus among patients of young age. Sibirskij medicinskij zhurnal. 2011;26(4-2):45-49. (In Russ.).

2. Zubkova NA, Gioeva OA, Tikhonovich YV, et al. Genotype-based personalized correction of glycemic control in patients with MODY due to mutations in GCK, HNF1A AND HNF4A genes. World Journal of Personalized Medicine. 2017;1(1):40-48. (In Russ.). doi: https://doi.org/10.14341/wjpm9298

3. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504-2508. doi: https://doi.org/10.1007/s00125-010-1799-4

4. Rubio-Cabezas O, Hattersley AT, Njølstad PR, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes. 2014;15(20):47-64. doi: https://doi.org/10.1111/pedi.12192.

5. Nyunt O, Wu JY, McGown IN, et al. Investigating Maturity Onset Diabetes of the Young. Clin Biochem Rev. 2009;30(2):67-74.

6. KuraevaTL, Sechko EA, Zilberman LI, et al. Molecular genetic and clinical variants MODY2 and MODY3 in children in Russia. Problems of Endocrinology. 2015;5:14-25. (In Russ.). doi: https://doi.org/10.14341/probl201561514-25

7. Voevoda MI, Shahshnejder EV, Ovsjannikova AK, et al. MODY: molekuljarno-geneticheskie determinanty i personalizirovannyj podhod k vedeniju pacientov s monogennymi formami saharnogo diabeta. Iz-vo SO RAN; 2019. (In Russ.).

8. Zubkova NA, Arbatskaya NYu, Petryaikina EE, et al. Type 3 form of MODY: the clinical and molecular-genetic characteristic. Nine cases of the disease. Problems of Endocrinology. 2014;60(1):51-56. (In Russ.). doi: https://doi.org/10.14341/probl201460151-56.

9. Sechko EA, Kuraeva TL, Zil’berman LI, et al. MODY3 in the children and adolescents: the molecular-genetic basis and clinico-laboratory manifestations. Problems of Endocrinology. 2015;3:16-22. (In Russ.) . doi: https://doi.org/10.14341/probl201561316-22

10. Kuraeva TL, Sechko EA, Eremina IA, et al. MODY3 in the child with type 2 diabetes mellitus phenotype: case report. Diabetes Mellitus. 2013;2:88-93. (In Russ.). doi: https://doi.org/10.14341/2072-0351-3762.

11. Steele AM, Wensley KJ, Ellard S, et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: Observational case control studie. PLoS ONE. 2013;8(6):e65326. doi: https://doi.org/10.1371/journal.pone.0065326

12. Fendler W, Małachowska B, Baranowska-Jazwiecka A, et al. Population based estimates for double diabetes amongst people with glucokinase monogenic diabetes, GCK-MODY. Diabet. Med. 2014;31(7):881-883. doi: https://doi.org/10.1111/dme.12449

13. Murphy R, Ellard S, Hattersley AT. Clinical implication of a molecular genetic classification of monogenic β–cell diabetes. Nature Clinical Practice. 2008;4(4):200-213. doi: https://doi.org/10.1038/ncpendmet0778

14. Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279-86. doi: https://doi.org/10.1001/jama.2013.283980

15. Pruhova S, Dusatkova P, Kraml PJ, et al. Chronic Mild Hyperglycemia in GCK-MODY Patients Does Not Increase Carotid Intima-Media Thickness. International Journal of Endocrinology. 2013;2013:1-5. doi: https://doi.org/10.1155/2013/718254

16. Ovsyannikova AK, Rymar OD, Shakhtshneider EV, et al. MODY in Siberia — molecular genetics and clinical characteristics. Diabetes mellitus. 2017;20(1):5-12. (In Russ.). doi: https://doi.org/10.14341/DM7920

17. Tosca MA, Silvestri M, Olcese R, et al. Allergic sensitization and symptoms, body mass index, and respiratory function in children with type 1 diabetes mellitus. Annals of Allergy. Asthma. Immunology. 2012;108(2):128-129. doi: https://doi.org/10.1016/j.anai.2011.12.002

18. Thanabalasingham G, Kaur K, Talbot F, et al. Atypical phenotype associated with reported GCK exon 10 deletions: Clinical judgement is needed alongside appropriate genetic investigations. Diabetic Medicine. 2013;30(8):233-238. doi: https://doi.org/10.1111/dme.12210

19. Shepherd MH, Shields BM, Hudson M, et al. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia. 2018;61(12):2520-2527. doi: https://doi.org/10.1007/s00125-018-4728-6

20. Katra B, Klupa T, Skupien J, et al. Dipeptidyl peptidase‐IV inhibitors are efficient adjunct therapy in HNF1A maturity‐onset diabetes of the young patients — report of two cases. Diabetes Technol Ther. 2010;12(4):313‐316. doi: https://doi.org/10.1089/dia.2009.0159

21. Østoft SH. Incretin hormones and maturity onset diabetes of the young‐pathophysiological implications and anti‐diabetic treatment potential. Dan Med J. 2015;62(9):2838-2844. doi: https://doi.org/10.2337/db13-1878.

22. Østoft SH, Bagger JI, Hansen T, et al. Postprandial incretin and islet hormone responses and dipeptidyl‐peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. Eur J Endocrinol. 2015;173(2):205‐215. doi: https://doi.org/10.1530/eje-15-0070